Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-2.92% $1.330
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 278.46 mill |
EPS: | -0.280 |
P/E: | -4.75 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 209.37 mill |
Avg Daily Volume: | 4.87 mill |
RATING 2024-04-25 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Sell | |
Return On Asset: | Buy | |
DE: | Strong Sell | |
P/E: | Strong Buy | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.75 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.81x |
Company: PE -4.75 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.125 - 1.535 ( +/- 15.41%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Dahan Michel | Sell | 8 661 | Common Stock |
2024-02-29 | Hadas Nicole R. | Sell | 5 974 | Common Stock |
2024-02-29 | Butler John P. | Sell | 46 570 | Common Stock |
2024-02-29 | Burke Steven Keith | Sell | 7 169 | Common Stock |
2024-02-27 | Hadas Nicole R. | Sell | 7 411 | Common Stock |
INSIDER POWER |
---|
87.62 |
Last 97 transactions |
Buy: 11 050 463 | Sell: 761 907 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.330 (-2.92% ) |
Volume | 2.54 mill |
Avg. Vol. | 4.87 mill |
% of Avg. Vol | 52.11 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.640 | N/A | Active |
---|
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.